Boron-Carbohydrate Complexes for Transient Calcitriol Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating calcitriol concentrations in mammals, such as dietary supplementation with Vitamin D3 or direct administration of calcitriol, are ineffective in achieving significant increases due to tightly regulated synthesis and degradation processes, and are associated with undesirable side effects like hypercalcemia and nausea.
Innovation Solution
The use of boron-containing compounds, specifically carbohydrate-boron complexes with a boron-ligand association constant between 3,000 and 20,000, administered orally in dosages between 100 mg and 1000 mg to produce a temporary spike in blood calcitriol concentration, effectively activating monocytes and modulating immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If dietary supplementation with Vitamin D3 or direct administration of calcitriol is used to increase calcitriol levels, then calcitriol synthesis substrate is increased, but the increase in calcitriol concentration is insignificant due to tightly regulated synthesis and degradation processes
Solution Approach 1:
The patent uses boron-containing compounds as intermediary substances that indirectly modulate calcitriol levels. Instead of directly administering calcitriol or its precursors, the boron compounds interact with the metabolic pathway (specifically inhibiting 24-hydroxylase activity) to achieve calcitriol accumulation. This intermediary approach bypasses the tightly regulated feedback mechanisms that limit direct supplementation effectiveness.
Solution Approach 2:
The invention changes the chemical parameters by introducing boron-containing compounds with specific molecular structures (such as boronate esters of sugars) that have different interaction properties with metabolic enzymes compared to natural vitamin D compounds. This parameter change allows modulation of the calcitriol degradation pathway without triggering the normal regulatory feedback that limits endogenous synthesis.
2Quantity of substance
If calcitriol is directly administered to increase serum concentration, then calcitriol levels are elevated, but undesirable side effects occur including hypercalcemia, excessive thirst and sweating, nausea, and constipation
Solution Approach 1:
The patent employs partial action by using low doses of boron-containing compounds that produce a moderate, controlled increase in calcitriol levels rather than the high levels achieved by direct calcitriol administration. This partial modulation of the degradation pathway achieves therapeutic benefits while avoiding the threshold for toxic effects and associated side effects.
Solution Approach 2:
By using boron compounds as intermediaries that selectively inhibit the degradation enzyme rather than directly supplementing calcitriol, the patent achieves a more gradual and controlled increase in calcitriol levels. This indirect approach allows the body's regulatory systems to respond more appropriately, preventing the abrupt elevation that causes hypercalcemia and other acute side effects.
3Quantity of substance
If Vitamin D3 supplementation is used to raise cholecalciferol levels, then substrate for calcitriol production is increased, but no significant increase in calcitriol can be achieved
Solution Approach 1:
The boron-containing compounds serve as intermediaries that act on the degradation pathway rather than the synthesis pathway. By inhibiting 24-hydroxylase activity, these compounds prevent calcitriol breakdown, allowing the naturally produced calcitriol from normal vitamin D metabolism to accumulate to therapeutic levels without needing to enhance synthesis rates.
Solution Approach 2:
Instead of trying to increase calcitriol production by enhancing synthesis (the conventional approach), the patent inverts the strategy by blocking the degradation pathway. This inverse approach to metabolic modulation achieves calcitriol accumulation by preventing its breakdown rather than by accelerating its formation, thereby bypassing the rate-limiting steps in synthesis.
Data Source
AI summary
Contemplated compositions and methods are drawn to use of various boron-containing compounds to temporarily and transiently increase endogenous blood calcitriol concentration. The boron-containing compound is preferably a carbohydrate-boron complex having sufficient stability to achieve measurable quantities of the complex in blood upon oral administration of the complex.